Elutia Inc

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Elutia Inc reports solid Q1 performance, eyes market disruption

Elutia Inc's Q1 2024 showcased strong revenue growth and operational improvements, with a focus on product line expansions and margin enhancement.
While facing challenges in gross margin decline and expense management, the company is strategically positioned to capitalize on market disruptions and growth opportunities.
By leveraging FDA clearances, product line strengths, and cost-saving initiatives, Elutia Inc aims to drive profitability and sustainable growth in the competitive healthcare market.

Elutia Inc reports stable Q2 performance and positions EluPro for market leadership

Elutia Inc's Q2 performance reflects stability and growth, supported by operational efficiency and strategic financial management.
The company's focus on EluPro's commercialization, expansion efforts, and market positioning underscores a commitment to innovation and market leadership.
While facing challenges in pricing and sales expansion, Elutia is well-positioned to capitalize on opportunities in diverse medical markets and drive long-term growth.

Elutia Inc reports positive Q3 earnings amidst operational challenges

Elutia Inc's Q3 performance showed positive net income but an EBITDA loss, with $5.9 million in sales.
Strengths include EluPro approval, expanding commercial footprint, and positive net income.
Challenges include EBITDA loss, rising operating expenses, and transitioning to EluPro.
Opportunities lie in SimpliDerm sales growth, market adoption of EluPro, and strategic investments.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Elutia, Inc. operates as a biotechnology company. It develops biologic products to improve compatibility between medical devices and the patients who need them. The firm operates through the following segments: Device Protection, Women’s Health, Orthobiologics and Cardiovascular. The Device Protection segment includes biological envelope that remodels into systematically connected, vascularized tissue for the long-term pocket protection of certain cardiac and neurostimulator implantable electronic vehicles. The Women’s Health segment includes pre-hydrated, human acellular dermal matrix, or HADM, that is designed to enable rapid integration, cellular repopulation and rapid revascularization at the surgical site. The Orthobiologics segment includes a variety of viable matrices, produced with a proprietary process that is designed to protect and preserve native bone cells and reduce programmable cell death, for use in bone repair and fusion procedures. The Cardiovascular segment includes a portfolio of extracellular matrices that retain the natural composition of collagen, growth factors and proteins for use in vascular and cardiac repair and pericardial closure. The company was founded by Kevin L. Rakin and Charles Randal Mills on August 6, 2015 and is headquartered in Silver Spring, MD.

SILVER SPRING, Md., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a company pioneering drug-eluting biomatrix products, today announced that it will release its third quarter 2023 financial results after market close on Monday, November 13, 2023. Members of the Company's management team will host a conference call and webcast starting at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on the same day.

Elutia to Report Third Quarter 2023 Financial Results on Monday, November 13, 2023

SILVER SPRING, Md., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a company pioneering drug-eluting biomatrix products, today announced that Dr. Randy Mills, President and Chief Executive Officer, will participate on a panel at the Cantor Global Healthcare Conference. The panel discussion will take place in New York on Wednesday, September 27, 2023, at 8:00 am ET.

Elutia to Participate in a Panel Discussion at the Cantor Global Healthcare Conference

Elutias (ELUT) gains on divestiture of Orthobiologics business unit for $35 million to Berkeley Biologics LLC, a wholly-owned subsidiary of GNI Group Ltd.

Elutias (ELUT) Up on Sale of Orthobiologics Business for $35M

– Combined proceeds of financing and Orthobiologics divestiture potentially top $60 million – SILVER SPRING, Md., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a company pioneering drug-eluting biomatrix products, today announced that it has entered into a securities purchase agreement for a private placement (PIPE) financing that is expected to result in initial gross proceeds to the Company of approximately $10.5 million, before deducting offering expenses.

Elutia Announces Private Placement for Proceeds Up to $26 Million

SILVER SPRING, Md., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a company pioneering drug-eluting biomatrix products, today announced the divestiture of the Company's Orthobiologics business unit to Berkeley Biologics LLC, a wholly owned subsidiary of GNI Group Ltd. Elutia will receive cash proceeds of up to $35 million, comprised of an upfront payment at closing of $15 million plus potential earnout payments of up to $20 million over a five-year period. The transaction is expected to close in the fourth quarter of 2023.

Elutia Announces Sale of Orthobiologics Business Unit for Cash Proceeds of Up to $35 Million

News for Elutia Inc Stock (ELUT)